The studies and legislation that matter, with primary sources. Updated July 2026.
The State of Texas awarded $50 million to UTMB Health, with UTHealth Houston, to lead IMPACT, a two-year multicenter clinical trial of ibogaine for PTSD, addiction and cognitive trauma. It is the largest public investment in ibogaine research to date and the clearest sign that US medical acceptance is being seriously tested.
Source: UTMB Health ↗A Stanford Medicine study published in Nature Medicine followed 30 US special-operations veterans with traumatic brain injury who received ibogaine with magnesium at a Mexican clinic. The cohort averaged an 88 percent reduction in PTSD symptoms with no serious cardiac events. The study was open-label and uncontrolled, so it is promising evidence, not proof.
Source: Stanford Medicine ↗Arizona, Kentucky, Nevada, New York, Oregon, Texas and Washington all introduced ibogaine access or research legislation in 2025, per the Legislative Analysis and Public Policy Association. Texas became the first to fund trials at scale.
Source: LAPPA ↗A preprint analyzing outcomes across international clinics reports substantially lower death rates under modern screening and monitoring protocols than historical estimates, with risk concentrated in opioid-dependent patients. The data is self-reported by clinics and not yet peer reviewed, so treat it as directional.
Source: Research Square (preprint) ↗